Tag: Alzheimer’s diseases

FDA, Regulations

FDA “collaborated” with Biogen on Aduhelm approval, says inquiry

December 30, 2022

Via: Pharmaphorum

The document produced by Oversight and Reform Committee chair Carolyn Maloney (D-NY) and Energy and Commerce Committee chair Frank Pallone Jr (D-NJ) also points to “collaboration” between Biogen and the FDA ahead of an advisory committee meeting that nevertheless resulted […]

Clinical Trials, Research and Development

Alzheimer’s and Down Syndrome Exhibit the Same Amyloid Beta Plaques and Tau Prions, Study Shows

November 21, 2022

Via: GEN

The brains of people with Down syndrome (DS) develop the same neurodegenerative tangles and plaques that are associated with Alzheimer’s disease (AD), and individuals with DS commonly exhibit signs of the neurodegenerative disorder in their forties or fifties. A new […]

Clinical Trials, Research and Development

Biogen, Eisai say lecanemab has aced phase 3 Alzheimer’s study

September 28, 2022

Via: Pharmaphorum

The highly-anticipated readout from the Clarity AD has shown that lecanemab met primary and secondary endpoints in patients with early-stage Alzheimer’s, said the two companies in a joint statement – although for now only the top-line results are being disclosed. […]